Clinical Trials in China / NCT07764588
Recruiting
Observational
Innate Immune Cell Phenotypes and Early Fibrotic Repair in Acute Myocardial Infarction
NCT07764588 · tracked via the Priya Life Science China tracker
Condition(s) studied
Myocardial Infarction
Study summary
To determine the relationship of the phenotypes of neutrophils and monocytes with early fibrotic repair after acute myocardial infarction.
Eligibility
Inclusion Criteria:
\---- Age \> 18 and ≤ 80 years old
\- Patients with acute STEMI within 12 hours of symptom onset who are planned to receive PPCI
Exclusion Criteria:
* Prior revascularization
* Known allergy to gadopentetate dimeglumine contrast agent
* Pregnancy or planned pregnancy within the next 6 months
* Life expectancy \< 1 year
* Metallic implants or claustrophobia that precluded MRI
* Severe COPD or inability to hold breath for MRI
* Severe hepatic or renal dysfunction (ALT \> 5×ULN or eGFR \< 15 mL/min/1.73 m²)
Primary outcome measure(s)
- Major cardiac adverse outcome — At 12 months after enrollment
The composite endpoint included cardiac death, non-fatal myocardial infarction, and rehospitalization for angina.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Shanghai Tenth People's Hospital | Shanghai | China | Recruiting |
More Shanghai 10th People's Hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07764588 on ClinicalTrials.gov ↗ ← All trials in China